GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Easton Pharmaceuticals Inc (OTCPK:EAPH) » Definitions » Tax Expense

EAPH (Easton Pharmaceuticals) Tax Expense : $0.00 Mil (TTM As of Sep. 2021)


View and export this data going back to . Start your Free Trial

What is Easton Pharmaceuticals Tax Expense?

Easton Pharmaceuticals's tax expense for the months ended in Sep. 2021 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2021 was $0.00 Mil.


Easton Pharmaceuticals Tax Expense Historical Data

The historical data trend for Easton Pharmaceuticals's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Easton Pharmaceuticals Tax Expense Chart

Easton Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec18 Dec19 Dec20
Tax Expense
Get a 7-Day Free Trial - - - - -

Easton Pharmaceuticals Quarterly Data
Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec18 Dec19 Dec20 Mar21 Jun21 Sep21
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Easton Pharmaceuticals Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Easton Pharmaceuticals  (OTCPK:EAPH) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Easton Pharmaceuticals Tax Expense Related Terms

Thank you for viewing the detailed overview of Easton Pharmaceuticals's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Easton Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8
Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.

Easton Pharmaceuticals Headlines

From GuruFocus

Easton Pharmaceuticals Announces BAYER Agreement Update

By Marketwired Marketwired 04-16-2018